New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - salbutamol sulfate 2mg - tablet - 2 mg - active: salbutamol sulfate 2mg excipient: gelatin lactose monohydrate magnesium stearate maize starch purified talc

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

bayer schering pharma - salbutamol - tablet - 2 mg

Ireland - English - HPRA (Health Products Regulatory Authority)

napp laboratories limited - salbutamol sulfate - tablets - 2 milligram

Ireland - English - HPRA (Health Products Regulatory Authority)

napp laboratories limited - salbutamol sulfate - tablets - 4 milligram

Ireland - English - HPRA (Health Products Regulatory Authority)

napp laboratories limited - tablets - 2 milligram

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - salbutamol sulfate 4mg - tablet - 4 mg - active: salbutamol sulfate 4mg excipient: gelatin lactose monohydrate magnesium stearate maize starch purified talc

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

bayer schering pharma - salbutamol - tablet - 4 mg

Ireland - English - HPRA (Health Products Regulatory Authority)

breath limited - salbutamol sulfate - nebuliser solution - 2.5/2.5 mg/ml

Ireland - English - HPRA (Health Products Regulatory Authority)

breath limited - salbutamol sulfate - nebuliser solution - 5/2.5 mg/ml

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - digoxin 0.25mg;  ;  ;  ;  ; digoxin 0.25mg - tablet - 0.25 mg - active: digoxin 0.25mg         excipient: lactose monohydrate magnesium stearate maize starch pregelatinised maize starch purified water rice starch active: digoxin 0.25mg excipient: lactose monohydrate magnesium stearate maize starch purified water rice starch starch, oxidised - cardiac failure:- lanoxin is indicated in the management of chronic cardiac failure where the dominant problem is systolic dysfunction. its therapeutic benefit is greatest in those patients with ventricular dilatation. lanoxin is specifically indicated where cardiac failure is accompanied by atrial fibrillation. supraventricular arrhythmias:- lanoxin is indicated in the management of certain supraventricular arrhythmias, particularly atrial flutter and fibrillation, where a major beneficial effect is reduction of the ventricular rate.